GoodRx Holdings Inc. (NASDAQ:GDRX) is one of the oversold stocks to buy now. On January 5, Bank of America analyst Allen Lutz lowered the firm’s price target on GoodRx to $2.60 from $3 and kept an Underperform rating on the shares. For the broader drug distributor sector, however, the firm remained positive heading into 2026 and adjusted its price targets to align with recent changes in valuation multiples across the peer group. Additionally, Morgan Stanley reduced its price target for GoodRx from $5 to ...